Association between pathologic gambling and Parkinsonian therapy as detected in the Food and Drug Administration adverse event database [4]

Archives of Neurology

Volumn 63, Issue 2, 2006, Pages 299-300

  Szarfman, Ana ^a   Doraiswamy, P Murali ^b   Tonning, Joseph M ^b   Levine, Jonathan G ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; NEUROLEPTIC AGENT; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE;

DATA BASE; FOOD AND DRUG ADMINISTRATION; HUMAN; IMPULSE CONTROL DISORDER; LETTER; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PRIORITY JOURNAL; SELF REPORT; STATISTICAL ANALYSIS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIPARKINSON AGENTS; DATABASES, FACTUAL; GAMBLING; HUMANS; LEVODOPA; PARKINSON DISEASE; REPRODUCIBILITY OF RESULTS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 32944458251     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.63.2.299-b     Document Type: Letter

References (3)

1. Dodd ML, Klos KJ, Bower JH, Geda YE, Josephs KA, Ahlskog JE. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol. 2005;62:1377-1381.
2. Szarfman A, Machado SG, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf. 2002;25:381-392.
3. Szarfman A, Tonning J, Doraiswamy PM. Pharmacovigilance in the 21st century: new tools for an old problem. Pharmacotherapy. 2004;24:1099-1104.